(function(){ var content_array=["
關于<\/b>GSK<\/b>:<\/b><\/p> \n
GSK是一家以科學為導向的全球醫療保健公司,旨在幫助人們能夠做到更多、感覺更舒適、生活更長久。如需更多信息,請訪問www.gsk.com<\/a>。<\/p> \n 參考文獻<\/b><\/p> \n 1. Chen WQ, Zheng RS, Baade PD,et al. Cancer Statistics in China<\/span>, 2015. CA CANCER J CLIN 2016;00:00–00:1-18<\/p> \n 2. Lei T, Mao WM, Lei TH.et al.Incidence and mortality trend of cervical cancer in 11 cancer registries of china.Chin J Cancer Res. 2011 ;23(1):10-4.<\/p> \n 3. 中華預防醫學會疫苗與免疫分會. 子宮頸癌等人乳頭瘤病毒相關疾病免疫預防專家共識 [J] . 中華預防醫學雜志,2019,53 (8): 761-803. DOI: 10.3760\/cma.j.issn.0253-9624.2019.08.001<\/p> \n 4. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva<\/span>: World Health Organization. Licence, 2020. CC BY-NC-SA 3.0 IGO.<\/p> \n 5. Puthanakit, T., et al., Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16\/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. J Infect Dis, 2016. 214(4): p. 525-36.<\/p> \n 6. Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule.<\/p> \n 7. Romanowski, B., et al., Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother, 2016. 12(1): p. 20-9.<\/p> \n 8. 中華預防醫學會婦女保健分會. 子宮頸癌綜合防控指南. 北京: 人民衛生出版社, 2017.<\/p> \n 9. Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clin Immunol 2016; 169: 16–27.<\/p> \n 10. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937–49.<\/p> \n 11. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: Improving upon nature. Gynecol Oncol 2008; 110: S1.<\/p> \n 12. GSK. GSK Cervarix®<\/sup> two-dose schedule receives European marketing authorization https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation\/<\/a><\/p> \n 13. Lyseng-Williamson, K.A., Human papillomavirus-16\/18 AS04-adjuvanted vaccine (cervarix(R)): a guide to its two-dose schedule in girls aged 9-14 years in the EU. Paediatr Drugs, 2014. 16(3): p. 247-53.<\/p> \n 14. Tay, S.K., et al., Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore<\/span>. Singapore Med J, 2018. 59(7): p. 370-382.<\/p> \n 15. Germar, M.J., et al., Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16\/18 vaccine compared with human papillomavirus 6\/11\/16\/18<\/span> vaccine in the Philippines<\/span>, with the new 2-dose schedule. Hum Vaccin Immunother, 2017. 13(5): p. 1158-1166.<\/p> \n 16. Van Kriekinge, G., et al., Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia<\/span>. Asian Pac J Cancer Prev, 2018. 19(4): p. 933-940.<\/p> \n 17. GSK. GSK internal tracking system for Global Regulatory Affairs.<\/p> \n 18. Descamps, D., et al., Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin, 2009. 5(5): p. 332-40.<\/p> \n 19. Angelo, M.G., et al., Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf, 2014. 23(5): p. 466-79.<\/p> \n 20. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland<\/span>: retrospective population study. BMJ. 2019 Apr 3<\/span>;365:l1161. doi: 10.1136\/bmj.l1161.<\/p> \n 21. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England<\/span>, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Nov 3:S0140-6736(21)02178-4.<\/p>"];
$("#dvExtra").html(content_array[0]);})();